Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Uproleselan - GlycoMimetics

Drug Profile

Uproleselan - GlycoMimetics

Alternative Names: APL-106; GMI-1271; Uproleselan injection - Apollomics/GlycoMimetics; Uproleselan sodium - GlycoMimetics

Latest Information Update: 05 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlycoMimetics
  • Developer Apollomics; GlycoMimetics; National Cancer Institute (USA); University of California, Davis
  • Class Antineoplastics; Antithrombotics; Glycolipids; Small molecules
  • Mechanism of Action E-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Gastrointestinal disorders
  • Phase I/II Acute biphenotypic leukaemia; COVID-19 pneumonia; Deep vein thrombosis; Myelodysplastic syndromes
  • No development reported Chronic myeloid leukaemia; Multiple myeloma; Solid tumours; Stem cell mobilisation

Most Recent Events

  • 03 Jan 2024 Apollomics completes enrolment in its phase-III clinical trial for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in China (IV) (NCT05054543)
  • 09 Dec 2023 Efficacy and adverse events data from a phase Ib/II trial in Acute myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 09 Dec 2023 Adverse events data from a phase II trial in Gastrointestinal disorders at 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top